04.21.25 -- STREAM Edition: Remind Me: Why Are We At Biotech War With China?

If you are in the process of developing a complex or sensitive injectable drug, learn about containment solutions to mitigate your risks and help you get your drug to the patient faster.

As a global, technology-driven CDMO, we provide product development through commercial manufacturing expertise focused on oral dosage forms for the Pharmaceutical industry. 

Early immunogenicity risk assessment can strengthen IND applications. Review the performance of a flow cytometry-based assay that enables a more comprehensive understanding of immunogenicity risk.

Ionizable lipids are key to optimizing lipid nanoparticle delivery, significantly enhancing the effectiveness of RNA vaccines, cell therapies, protein replacement, and gene editing.

Examine nitrites in excipients, nitrosamine risks, regulatory considerations, analytical controls, and a case study on mitigating risks in pharmaceutical manufacturing and storage.

With over 6,000 tooling parts and an in-house machining center to ensure precision, explore this versatile blister service that provides both Thermoformed and Cold-Formed solutions.

Learn the fundamentals of developing a continuous chromatography process with Simulated Moving Bed (SMB) technology for small molecules, from gram-scale to multi-ton commercial production.

Focusing on biologics, vaccines, nucleic acids, and gene therapy, our Boston facility is now a commercially licensed site boasting a 10x 2,000L drug substance manufacturing capacity.

It’s hard to focus on the issues that precipitated the challenges and proscribed solutions to so much of our supply chain being in China. IP was (and should be) at the center of the discussion.

Gain insight into how UPD ensures scalable and compliant processes, facilitates the efficient development of innovative therapeutics, and contributes to molecule development and production.